NEO100 for children with high-grade brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called NEO100 for children with certain types of brain tumors. It is given through a needle into the tumor or nearby fluid, and the study looks at safety and the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 18 years old.
- You need a type of pediatric brain tumor called a high-grade glioma, including tumors like diffuse midline glioma or those affecting the brainstem.
- You should be able to do daily activities, even if you need a wheelchair (a score of 50 or more on a performance scale).
- If you have had previous treatments, you must be at least 4 weeks past them and have recovered from side effects.
- Your kidneys, liver, and blood counts must be working well enough (doctors will check with tests).
- You cannot have other serious health issues like uncontrolled infections, heart problems, or certain other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
This trial studies NEO100, a treatment for adults and children (age 12+) with Grade II or III meningioma that has come back or kept growing after surgery and radiation. It may help shrink tumors or slow growth when standard options have not worked well enough.
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Hear when a new Diffuse Midline Glioma, H3 K27M-Mutant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.